Zerumbone inhibits tumor angiogenesis via NF-κB in gastric cancer

Oncology Reports

Volumn 31, Issue 1, 2014, Pages 57-64

  Tsuboi, Ken ^a   Matsuo, Yoichi ^a   Shamoto, Tomoya ^a   Shibata, Takahiro ^a   Koide, Shuji ^a   Morimoto, Mamoru ^a   Guha, Sushovan ^b   Sung, Bokyung ^c   Aggarwal, Bharat B ^c   Takahashi, Hiroki ^a   Takeyama, Hiromitsu ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Angiogenesis; Gastric cancer; Vascular endothelial growth factor; Zerumbone

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; VASCULOTROPIN; ZERUMBONE;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; SESQUITERPENES; STOMACH NEOPLASMS; TRANSCRIPTION FACTOR RELA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84891922829     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2842     Document Type: Article

References (60)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 13: 2893-2917, 2010.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 13: 69-90, 2011.
3. Hartgrink HH, Jansen EP, van Grieken NC and van de Velde CJ: Gastric cancer. Lancet 13: 477-490, 2009.
4. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A and Fleig WE: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24: 2903-2909, 2006.
5. Matsuo Y, Sawai H, Funahashi H, et al: Enhanced angiogenesis due to inflammatory cytokines from pancreatic cancer cell lines and relation to metastatic potential. Pancreas 28: 344-352, 2004.
6. Tong Z, Kunnumakkara AB, Wang H, et al: Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. Cancer Res 68: 6100-6108, 2008.
7. Matsuo Y, Sawai H, Ochi N, et al: Interleukin-1alpha secreted by pancreatic cancer cells promotes angiogenesis and its therapeutic implications. J Surg Res 153: 274-281, 2009.
8. Matsuo Y, Ochi N, Sawai H, et al: CXCL8/IL-8 and CXCL12/SDF-1alpha co-operatively promote invasiveness and angio genesis in pancreatic cancer. Int J Cancer 124: 853-861, 2009.
9. Matsuo Y, Sawai H, Ma J, et al: IL-1alpha secreted by colon cancer cells enhances angiogenesis: the relationship between IL-1alpha release and tumor cells' potential for liver metastasis. J Surg Oncol 99: 361-367, 2009.
10. Matsuo Y, Sawai H, Ochi N, et al: Proteasome inhibitor MG132 inhibits angiogenesis in pancreatic cancer by blocking NF-kappaB activity. Dig Dis Sci 55: 1167-1176, 2010.
11. Matsuo Y, Raimondo M, Woodward TA, et al: CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer. Int J Cancer 125: 1027-1037, 2009.
12. Matsuo Y, Campbell PM, Brekken RA, et al: K-Ras promotes angiogenesis mediated by immortalized human pancreatic epithelial cells through mitogen-activated protein kinase signaling pathways. Mol Cancer Res 7: 799-808, 2009.
13. Carmeliet P: Angiogenesis in health and disease. Nat Med 9: 653-660, 2003.
14. Ma J, Sawai H, Matsuo Y, et al: Interleukin-1alpha enhances angiogenesis and is associated with liver metastatic potential in human gastric cancer cell lines. J Surg Res 148: 197-204, 2008.
15. Maeda K, Chung YS, Ogawa Y, et al: Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 77: 858-863, 1996.
16. Maeda K, Kang SM, Onoda N, et al: Vascular endothelial growth factor expression in preoperative biopsy specimens correlates with disease recurrence in patients with early gastric carcinoma. Cancer 86: 566-571, 1999.
17. Kikuchi S, Obata Y, Yagyu K, et al: Reduced serum vascular endothelial growth factor receptor-2 (sVEGFR-2) and sVEGFR-1 levels in gastric cancer patients. Cancer Sci 102: 866-869, 2011.
18. Karayiannakis AJ, Syrigos KN, Polychronidis A, et al: Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg 236: 37-42, 2002.
19. Kim KK and Kim HB: Protein interaction network related to Helicobacter pylori infection response. World J Gastroenterol 15: 4518-4528, 2009.
20. Varro A, Noble PJ, Pritchard DM, et al: Helicobacter pylori induces plasminogen activator inhibitor 2 in gastric epithelial cells through nuclear factor-kappaB and RhoA: implications for invasion and apoptosis. Cancer Res 64: 1695-1702, 2004.
21. Keates S, Hitti YS, Upton M and Kelly CP: Helicobacter pylori infection activates NF-kappa B in gastric epithelial cells. Gastroenterology 113: 1099-1109, 1997.
22. Xiong HQ, Abbruzzese JL, Lin E, Wang L, Zheng L and Xie K: NF-kappaB activity blockade impairs the angiogenic potential of human pancreatic cancer cells. Int J Cancer 108: 181-188, 2004.
23. Beg AA and Baldwin AS Jr: The I kappa B proteins: multifunc tional regulators of Rel/NF-kappa B transcription factors. Genes Dev 7: 2064-2070, 1993.
24. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D and Miyamoto S: Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev 9: 2723-2735, 1995.
25. Nam SY, Ko YS, Jung J, et al: A hypoxia-dependent upregulation of hypoxia-inducible factor-1 by nuclear factor-κB promotes gastric tumour growth and angiogenesis. Br J Cancer 104: 166-174, 2011.
26. Nakata W, Hayakawa Y, Nakagawa H, et al: Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer. Int J Oncol 39: 1529-1536, 2011.
27. Caballero-Velázquez T, López-Corral L, Encinas C, et al : Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients. Br J Haematol 162: 474-482, 2013.
28. Gupta SC, Kim JH, Prasad S, et al: Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 29: 405-434, 2010.
29. Yob NJ, Jofrry SM, Affandi MM, et al: Zingiber zerumbet (L.) Smith: a review of its ethnomedicinal, chemical, and pharma cological uses. Evid Based Complement Alternat Med 2011: 543216, 2011.
30. Murakami A, Takahashi D, Kinoshita T, et al: Zerumbone, a Southeast Asian ginger sesquiterpene, markedly suppresses free radical generation, proinflammatory protein production, and cancer cell proliferation accompanied by apoptosis: the alpha, beta-unsaturated carbonyl group is a prerequisite. Carcinogenesis 23: 795-802, 2002.
31. Sung B, Jhurani S, Ahn KS, et al: Zerumbone down-regulates chemokine receptor CXCR4 expression leading to inhibition of CXCL12-induced invasion of breast and pancreatic tumor cells. Cancer Res 68: 8938-8944, 2008.
32. Yodkeeree S, Sung B, Limtrakul P and Aggarwal BB: Zerumbone enhances TRAIL-induced apoptosis through the induction of death receptors in human colon cancer cells: evidence for an essential role of reactive oxygen species. Cancer Res 69: 6581-6589, 2009.
33. Kirana C, McIntosh GH, Record IR and Jones GP: Antitumor activity of extract of Zingiber aromaticum and its bioactive sesquiterpenoid zerumbone. Nutr Cancer 45: 218-225, 2003.
34. Kim M, Miyamoto S, Yasui Y, Oyama T, Murakami A and Tanaka T: Zerumbone, a tropical ginger sesquiterpene, inhibits colon and lung carcinogenesis in mice. Int J Cancer 124: 264-271, 2009.
35. Xian M, Ito K, Nakazato T, et al : Zerumbone, a bioactive sesquiterpene, induces G2/M cell cycle arrest and apoptosis in leukemia cells via a Fas- and mitochondria-mediated pathway. Cancer Sci 98: 118-126, 2007.
36. Huang GC, Chien TY, Chen LG and Wang CC: Antitumor effects of zerumbone from Zingiber zerumbet in P-388D1 cells in vitro and in vivo. Planta Med 71: 219-224, 2005.
37. Sakinah SA, Handayani ST and Hawariah LP: Zerumbone induced apoptosis in liver cancer cells via modulation of Bax/Bcl-2 ratio. Cancer Cell Int 7: 4, 2007.
38. Sung B, Murakami A, Oyajobi BO and Aggarwal BB: Zerumbone abolishes RANKL-induced NF-κB activation, inhibits osteoclastogenesis, and suppresses human breast cancer-induced bone loss in athymic nude mice. Cancer Res 69: 1477-1484, 2009.
39. Takada Y, Murakami A and Aggarwal BB: Zerumbone abolishes NF-κB and I κBα kinase activation leading to suppression of antiapoptotic and metastatic gene expression, upregulation of apoptosis, and downregulation of invasion. Oncogene 24: 6957-6969, 2005.
40. Chen D, Frezza M, Schmitt S, Kanwar J and Dou QP: Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspective. Curr Cancer Drug Targets 11: 239-253, 2011.
41. Aggarwal BB, Van Kuiken ME, Iyer LH, Harikumar KB and Sung B: Molecular targets of nutraceuticals derived from dietary spices: potential role in suppression of inflammation and tumorigenesis. Exp Biol Med 234: 825-849, 2009.
42. Li-Weber M: New therapeutic aspects of flavones: the anti cancer properties of Scutellaria and its main active constituents Wogonin, Baicalein and Baicalin. Cancer Treat Rev 35: 57-68, 2009.
43. Harikumar KB, Sung B, Tharakan ST, et al: Sesamin manifests chemopreventive effects through the suppression of NF-kappa B-regulated cell survival, proliferation, invasion, and angiogenic gene products. Mol Cancer Res 8: 751-761, 2010.
44. Bhuiyan NI, Chowdhury JU and Begum J: Chemical inves tigation of the leaf and rhizome essential oils of Zingiber zerumbet (L.) Smith from Bangladesh. Bangladesh J Pharmacol 4: 9-12, 2009.
45. Zakaria ZA, Mohamad AS, Chear CT, Wong YY, Israf zDA and Sulaiman MR: Antiinflammatory and antinociceptive activities of Zingiber zerumbet methanol extract in experimental model systems. Med Princ Pract 19: 287-294, 2010.
46. Zakaria ZA, Mohamad AS, Ahmad MS, et al: Preliminary analysis of the anti-inflammatory activity of essential oil of Zingiber zerumbet. Biol Res Nurs 13: 425-432, 2011.
47. Tushar, Basak S, Sarma GC and Rangan L: Ethnomedical uses of Zingiberaceous plants of Northeast India. J Ethnopharmacol 132: 286-296, 2010.
48. Somchit MN and Shukriyah MHN: Antiinflammatory property of ethanol and water extracts of Zingiber zerumbet. Indian J Pharmacol 35: 181-182, 2003.
49. Somchit MN, Shukriyah MHN, Bustamam AA and Zuraini A: Anti-pyretic and analgesic activity of Zingiber zerumbet. Int J Pharmacol 1: 277-280, 2005.
50. Sulaiman MR, Tengku Mohamad TA, Shaik Mossadeq WM, et al: Antinociceptive activity of the essential oil of Zingiber zerumbet. Planta Med 76: 107-112, 2010.
51. Jantan IB, Yassin MS, Chin CB, Chen LL and Sim NL: Antifungal activity of the essential oils of nine Zingiberaceae species. Pharm Biol 41: 392-397, 2003.
52. Voravuthikunchai SP, Phongpaichit S and Subhadhirasakul S: Evaluation of antibacterial activities of medicinal plants widely used among AIDS patients in Thailand. Pharm Biol 43: 701-706, 2005.
53. Voravuthikunchai SP, Limsuwan S, Supapol O and Subha dhirasakul S: Antibacterial activity of extracts from family Zingiberaceae against foodborne pathogens. J Food Safety 26: 325-334, 2005.
54. Phongpaichit S, Vuddhakul V, Subhadhirasakul S and Wattanapiromsakul C: Evaluation of the antimycobacterial activity of extracts from plants used as self-medication by AIDS patients in Thailand. Pharm Biol 44: 71-75, 2006.
55. Tewtrakul S and Subhadhirasakul S: Anti-allergic activity of some selected plants in the Zingiberaceae family. J Ethnopharmacol 109: 535-538, 2007.
56. Murakami A and Ohigashi H: Targeting NOX, INOS and COX-2 in inflammatory cells: chemoprevention using food phyto chemicals. Int J Cancer 121: 2357-2363, 2007.
57. Murakami A, Shigemori T and Ohigashi H: Zingiberaceous and citrus constituents, 10-acetoxychavicol acetate, zerumbone, auraptene, and nobiletin, suppress lipopolysaccharide-induced cyclooxygenase-2 expression in RAW264.7 murine macro phages through different modes of action. J Nutr 135 (Suppl 12): 2987-2992, 2005.
58. Maeda S, Yoshida H, Ogura K, et al : H. pylori activates NF-kappaB through a signaling pathway involving IkappaB kinases, NF-kappaB-inducing kinase, TRAF2, and TRAF6 in gastric cancer cells. Gastroenterology 119: 97-108, 2000.
59. Lamb A and Chen LF: Role of the Helicobacter pylori-induced inflammatory response in the development of gastric cancer. J Cell Biochem 114: 491-497, 2013.
60. Yin Y, Si X, Gao Y, Gao L and Wang J: The nuclear factor-κB correlates with increased expression of interleukin-6 and promotes progression of gastric carcinoma. Oncol Rep 29: 34-38, 2013.